AD/PD 2023 | Past and future of immunotherapy in Alzheimer’s disease

Mourad Tayebi, PhD, Western Sydney University, Penrith, Australia, explains the current outlook of the field of immunotherapy in Alzheimer’s disease. In the past, a lack of understanding led to a hit-and-miss approach to drug development. However, advancements in bioinformatics can now support a systematized approach, informing us of the types of epitope that can be used to generate non-toxic and non-allergenic antibodies. While a lack of rigorous characterization of putative therapeutic antibodies has led to setbacks, the knowledge gained is informing current studies. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.